BioNexus Gene Lab Corp (BGLC) BioNexus Gene Lab Corp. (BGLC), established in 2017 and headquartered in Kuala Lumpur, Malaysia, conducts business through two primary subsidiaries. Its subsidiary, Chemrex Corporation Sdn. Bhd., specializes in the wholesale distribution of chemical raw material products across Malaysia, Indonesia, Vietnam, and other nations within Southeast Asia. These essential chemicals are utilized in the manufacturing of a wide array of products, including handrails, bench tops, components for the automotive and aerospace industries, cleanroom panels, and various instruments. Additionally, through its other subsidiary, BioNexus Gene Lab Sdn. Bhd., the company is involved in the development and provision of non-invasive liquid biopsy tests, designed for the early detection of biomarkers.
Sector: Services-Medical Laboratories
Industry: Industrial - Distribution
BioNexus Gene Lab Corp. NASDAQ:BGLC Industrials · Industrial - Distribution
Mkt Cap $2.25M
EV -
SI 0.3%
Net Cash/Sh -
AH After hours -2.00%$0.7509 Prev close $0.8200 -6.56%Close $0.7662 -2.00%Now $0.7509 VOL 14K $ Vol $10K RVOL 2.52x
Mkt Cap $2.25M
EV -
VOL 14K sh
$ Vol $10K
RVOL 2.52×
SI 0.3%
Net Cash/Sh -
Press Release
BioNexus Launches BGLC 1Lab Pilot for GeneMatrix Workflows at MRNA Scientific
BioNexus Gene Lab launched BGLC 1Lab, a laboratory workflow product, as a controlled GeneMatrix-focused pilot at its MRNA Scientific subsidiary in Penang, Malaysia. The pilot tests traceability and staff review across clinic orders through report delivery, with plans for secure reporting and private AI Q&A; clinical release remains subject to validation and regulatory reviews. BioNexus also intends to integrate Ruanyun Edai Technology's (RYET) CogniAI document-intelligence platform into 1Lab, but that license agreement, dated October 5, 2026, has not closed and remains subject to due diligence and approvals.
• 14d ago AI analysis › Press Release
BioNexus Launches New Corporate Website with Expanded Business and Investor Resources
BioNexus Gene Lab Corp. launched a redesigned corporate website consolidating information on its RNA screening, industrial chemicals, and healthcare investment businesses. The site highlights the VitaGuard molecular residual disease platform and blood-based genomic screening technology, alongside an expanded investor-relations section with SEC filings and governance materials.
• 18d ago AI analysis › Press Release
BioNexus to Build AI Applications for Malaysian Healthcare Under Exclusive CogniAI Licence
BioNexus Gene Lab (BGLC) signed a definitive agreement with Ruanyun Edai Technology (RYET) for a 10-year exclusive Malaysian healthcare licence to the CogniAI document-intelligence platform. BGLC will pay the US$3.5 million licence consideration entirely in stock (410,000 shares) plus 150,000 shares in a share exchange, with a 10% royalty to RYET on receipts collected and no cash outlay.
• 1mo ago AI analysis › Press Release
RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab
BGLC signed a definitive agreement for an exclusive 10-year license (extendable to 20 years) of RYET's Cogni AI platform for healthcare in Malaysia, with a 10% royalty to RYET and the right to expand into other Malaysian industries. BGLC would pay US$3.5 million in license consideration via 410,000 shares (quoted value US$520,700 at Oct 2 closes) and issue 150,000 additional shares in a reciprocal exchange for 500,000 RYET shares. The deal has not closed: it requires BGLC acceptance testing, due diligence, regulatory approvals, and a PRC export license RYET has not obtained, and either party may terminate if closing has not occurred by March 31, 2027.
• 1mo ago AI analysis › Press Release
BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit
BioNexus is advancing the commercial rollout of its licensed VitaGuard liquid-biopsy platform in Southeast Asia following a strategic working visit to the Tongshu Gene group in China. The visit focused on technical planning and implementation requirements for the region, which covers a population of over 680 million, with BioNexus targeting initial deployments in select medical hubs during 2026.
• 3mo ago AI analysis › Press Release
BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development
BioNexus Gene Lab Corp. highlighted CEO Sam Tan’s participation in the 2026 China–Malaysia Economic Cooperation Outlook Forum in Kuala Lumpur. Tan advocated for moving biotechnology cooperation between Malaysia and China beyond traditional trade into deeper models of co-development, clinical validation, and commercialization.
• 5mo ago AI analysis ›